
Sign up to save your podcasts
Or


Biogen falls 30% after halting trials for its Alzheimer’s drug. Healthcare analyst (and Industry Focus host) Shannon Jones discusses potential next moves for the suddenly-embattled pharmaceutical company. CVS starts selling cannabis products in eight states. Plus, a federal judge sides with the maker of Dum Dum lollipops in a battle against Tootsie Roll.
Get $50 off your first job post at www.LinkedIn.com/Fool.
By The Motley Fool4.7
16041,604 ratings
Biogen falls 30% after halting trials for its Alzheimer’s drug. Healthcare analyst (and Industry Focus host) Shannon Jones discusses potential next moves for the suddenly-embattled pharmaceutical company. CVS starts selling cannabis products in eight states. Plus, a federal judge sides with the maker of Dum Dum lollipops in a battle against Tootsie Roll.
Get $50 off your first job post at www.LinkedIn.com/Fool.

3,216 Listeners

1,491 Listeners

806 Listeners

945 Listeners

524 Listeners

1,166 Listeners

2,181 Listeners

825 Listeners

1,423 Listeners

1,036 Listeners

9,715 Listeners

197 Listeners

826 Listeners

85 Listeners

591 Listeners

1,026 Listeners

53 Listeners